BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 19019674)

  • 1. Fragment-based discovery of JAK-2 inhibitors.
    Antonysamy S; Hirst G; Park F; Sprengeler P; Stappenbeck F; Steensma R; Wilson M; Wong M
    Bioorg Med Chem Lett; 2009 Jan; 19(1):279-82. PubMed ID: 19019674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
    Wang T; Ledeboer MW; Duffy JP; Salituro FG; Pierce AC; Zuccola HJ; Block E; Shlyakter D; Hogan JK; Bennani YL
    Bioorg Med Chem Lett; 2010 Jan; 20(1):153-6. PubMed ID: 19945871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B.
    Collins I; Caldwell J; Fonseca T; Donald A; Bavetsias V; Hunter LJ; Garrett MD; Rowlands MG; Aherne GW; Davies TG; Berdini V; Woodhead SJ; Davis D; Seavers LC; Wyatt PG; Workman P; McDonald E
    Bioorg Med Chem; 2006 Feb; 14(4):1255-73. PubMed ID: 16249095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
    Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based ligand discovery.
    Fischer M; Hubbard RE
    Mol Interv; 2009 Feb; 9(1):22-30. PubMed ID: 19299661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination.
    Griffin RJ; Henderson A; Curtin NJ; Echalier A; Endicott JA; Hardcastle IR; Newell DR; Noble ME; Wang LZ; Golding BT
    J Am Chem Soc; 2006 May; 128(18):6012-3. PubMed ID: 16669651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two 'Golden Ratio' indices in fragment-based drug discovery.
    Orita M; Ohno K; Niimi T
    Drug Discov Today; 2009 Mar; 14(5-6):321-8. PubMed ID: 19028598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
    Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
    J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
    van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
    Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery.
    Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L
    Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of spirocyclic sulfonamides as potent Akt inhibitors with exquisite selectivity against PKA.
    Xu R; Banka A; Blake JF; Mitchell IS; Wallace EM; Bencsik JR; Kallan NC; Spencer KL; Gloor SL; Martinson M; Risom T; Gross SD; Morales TH; Wu WI; Vigers GP; Brandhuber BJ; Skelton NJ
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2335-40. PubMed ID: 21420856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches.
    Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I
    J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of Free-Wilson selectivity analysis for combinatorial library design.
    Sciabola S; Stanton RV; Johnson TL; Xi H
    Methods Mol Biol; 2011; 685():91-109. PubMed ID: 20981520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and PKCtheta inhibitory activity of a series of 5-vinyl phenyl sulfonamide-3-pyridinecarbonitriles.
    Shim J; Eid C; Lee J; Liu E; Chaudhary D; Boschelli DH
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6575-7. PubMed ID: 19854645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.
    Labadie S; Dragovich PS; Barrett K; Blair WS; Bergeron P; Chang C; Deshmukh G; Eigenbrot C; Ghilardi N; Gibbons P; Hurley CA; Johnson A; Kenny JR; Kohli PB; Kulagowski JJ; Liimatta M; Lupardus PJ; Mendonca R; Murray JM; Pulk R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward S; Zak M
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7627-33. PubMed ID: 23107482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.